Summary

Among patients with atrial fibrillation (AF) treated with anticoagulants, differences in baseline characteristics only partially account for the differences in outcome by AF subtype. This article presents results of a secondary data analysis from the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation—Thrombolysis in Myocardial Infarction 48 trial [ENGAGE AF-TIMI 48; NCT00781391].